Hypoglycemic Effect of Fermented Soymilk Extract in STZ-induced Diabetic Mice

  • Yi, Na-Ri (Department of Food Science and Nutrition, Pusan National University) ;
  • Hwang, Ji-Young (Department of Food Science and Nutrition, Pusan National University) ;
  • Han, Ji-Sook (Department of Food Science and Nutrition, Pusan National University)
  • Published : 2009.03.31


This study investigated the hypoglycemic effect of fermented soymilk extract (FSE) in STZ-induced diabetic mice. FSE was prepared via fermentation of soymilk with Bacillus subtilis followed by methanol extraction. The hypoglycemic effect was determined by inhibitory activities against ${\alpha}$-glucosidase and ${\alpha}$-amylase as well as the alleviation of postprandial glucose level. The non-fermented soymilk extract (SE) was used as control in this experiment. FSE showed higher (p<0.05) inhibitory activities than SE against ${\alpha}$-glucosidase and ${\alpha}$-amylase. The $IC_{50}$ values of FSE for ${\alpha}$-glucosidase and ${\alpha}$-amylase were 0.77 ancd 0.94 mg/mL, respectively, which were comparable or even superior to those of acarbose (0.79 and 0.68 mg/mL, respectively). In addition, a further suppression on the postprandial blood glucose levels were observed in the FSE than SE group for both STZ-induced diabetic mice and normal mice. Furthermore, FSE significantly lowered the incremental area under the curve (AUC) in the diabetic mice and the AUC in normal mice corroborated the hypoglycemic effect of FSE (p<0.05). Results from this study suggest that FSE may help decrease the postprandial blood glucose level via inhibiting ${\alpha}$-glucosidase and ${\alpha}$-amylase and the usefulness of FSE was proven to be better than SE.


  1. Corry DB, Tuck ML. 2000. Protection from vascular risk in diabetic hypertension. Curr Hypertens Rep 2: 154-159
  2. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA. 2000. Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321: 405-412
  3. The Diabetes Control and Complications Trial (DCCT) Research Group. 1993. The effect of intensive treatment of diabetes on the development and progression of long-term complications in the diabetes control in insulin-dependent diabetes mellitus. N Engl J Med 329: 977-986
  4. UK Prospective Diabetes Study (UKPDS) Group. 1998. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317: 703-713
  5. Abrahaamson MJ. 2004. Optimal glycemic control in type 2 diabetes mellitus: fasting and postprandial glucose in context. Arch Intern Med 164: 486-491
  6. Avignon A, Radauceanu A, Monnier L. 1997. Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes. Diabetes Care 20: 1822-1826
  7. Veciana M, Major CA, Morgan MA, Asrat T, Toohey JS, Lien JM, Evans AT. 1995. Postprandial versus preprandial blood glucose monitoring in women with gestational diabetes mellitus requiring insulin therapy. N Engl J Med 333: 1237-1241
  8. Lebovitz HE. 2001. Effect of the postprandial state on nontraditional risk factors. Am J Cardiol 88: 20H-25H
  9. Jermendy G. 2005. Can type 2 diabetes mellitus be considered preventable? Diabetes Res Clin Prac 68: S73-S81
  10. Holman RR, Cull CA, Turner RC. 1999. A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (UK Prospective Diabetes Study 44). Diabetes Care 22: 960-964
  11. Toeller M. 1994. $\alpha$-Glucosidase inhibitors in diabetes: efficacy in NIDDM subjects. Eur J Clin Invest 24: 31-35
  12. Clissold SP, Edwards C. 1988. A preliminary review of its pharmacodynamic and pharmacokinetics properties, and therapeutic potential. Drugs 35: 214-243
  13. Saito N, Sakai H, Sekihara H, Yajima Y. 1998. Effect of an $\alpha$-glucosidase inhibitor (voglibose), in combination with sulphonilureas, on glycemic control in type 2 diabetes patients. J Int Med Res 26: 219-232
  14. Balflour JA, McTavish D. 1993. Acarbose. An update of its pharmacology and therapeutic use in diabetes mellitus. Drugs 46: 1025-1054
  15. Coniff RF, Shapiro JA, Robbins D, Kleinfield R, Scaton TB, Beisswenger P, McGill JB. 1995. Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. Diabetes Care 18: 817-824
  16. Standl E, Baumgartl HJ, Fuchtenbusch M, Stemplinger J. 1999. Effect of acarbose on additional insulin therapy in type 2 diabetic patients with late failure of sulphonylurea therapy. Diabetes Obes Metab 1: 215-220
  17. Hansawasdic C, Kawabata J, Kasai T. 2000. $\alpha$-Amylase inhibitors from roselle (Hibiscus sabdariffa Linn.) tea. Biosci Biotechnol Biochem 64: 1041-1043
  18. Hanefeld M. 1998. The role of acarbose in the treatment of non-insulin-dependent diabetes mellitus. J Diabetes Complicat 12: 228-237
  19. Asano N, Yamashita T, Yasuda K, Ikeda K, Kizu H, Kameda Y. 2001. Polyhydroxylated alkaloids isolated from mulberry trees (Morusalba L.) and silkworms (Bombyx mori L.). J Agric Food Chem 49: 4208-4213
  20. Hiroyuki F, Tomohide Y, Kazunori O. 2001. Efficacy and safety of Touchi extract, an alpha-glucosidase inhibitor derived from fermented soybeans, in non-insulin-dependent diabetic mellitus. J Nutr Biochem 12: 351-356
  21. Lee DS, Lee SH. 2001. Genistein, a soy isoflavone, is a potent alpha glucosidase inhibitor. FEBS Lett 501: 84-86
  22. Matsui T, Ueda T, Oki T, Sugita K, Terahara N, Matsumoto K. 2001. Alpha-glucosidase inhibitory action of natural acylated anthocyanins. 1. Survey of natural pigments with potent inhibitory activity. J Agric Food Chem 49: 1948-1951
  23. Wang YC, Yu RC, Chou CC. 2006. Antioxidative activities of soymilk fermented with lactic acid bacteria and bifidobacteria. Food Microbiol 23: 128-135
  24. Anderson JW, Johnstone BM, Cook N. 1995. Meta-analysis of the effects of soy protein intake on serum lipids. N Engl J Med 333: 276-282
  25. Potter SM. 1998. Soy protein and cardiovascular disease: the impact of bioactive components in soy. Nutr Rev 56: 231-235
  26. Hermansen K, Sondergaard M, Hoie L, Carstensen M, Brock B. 2001. Beneficial effects of a soy-based dietary supplement on lipid levels and cardiovascular risk markers in type 2 diabetic subjects. Diabetes Care 24: 228-233
  27. Anderson JB, Anthony M, Messina M, Garner SC. 1999. Effects of phyto-estrogens on tissues. Nutr Res Rev 12: 75-116
  28. Bingham SA, Atkinson C, Liggins J, Bluck L, Coward A. 1998. Phyto-estrogens: where are we now? Br J Nutr 79: 393-406
  29. Setchell KDR, Cassidy A. 1999. Dietary isoflavones: biological effects and relevance to human health. J Nutr 129: 758S-767S
  30. Rebeca FO, Juana F, Rosario M, Henryk Z, Mariusz KP, Halina K, Concepcion V. 2007. Fermentation as a bio process to obtain functional soybean flours. J Agric Food Chem 55: 8872-8979
  31. Kuo LC, Cheng WY, Wu RY, Huang CJ, Lee KT. 2006. Hydrolysis of black soybean isoflavone glycosides by Bacillus subtilis natto. Appl Microbiol Biotechnol 73: 314-320
  32. Watanabe J, Kawabata J, Kurihara H, Niki R. 1997. Isolation and identification of alpha-glucosidase inhibitors from Tochucha (Eucommia ulmoides). Biosic Biotechnol Biochem 61: 177-178
  33. Kim JS. 2004. Effect of Rhemanniae Radix on the hyperglycemic mice induced with streptozotocin. J Korean Soc Food Sci Nutr 33: 1133-1138
  34. Lebovitz HE. 1997. Alpha-glucosidase inhibitors. Endocrin Metab Clin 26: 539-551
  35. Hara Y, Honda M. 1990. The inhibition of $\alpha$-amylase by tea polyphenols. Agric Biol Chem 54: 1939-1945
  36. Li Y, Wen S, Kota BP, Peng G, Li GQ, Yamahara J, Roufogalis BD. 2005. Punica granatum flower extract, a potent $\alpha$-glucosidase inhibitor, improves postprandial hyperglycemia in Zucker diabetic fatty rats. J Ethnopharmacol 99: 239-244
  37. Savitry A, Prakash M. 2004. Sing a song of soy. Prepared Food 4: 25-28
  38. Kim JS, Kwon JS, Son KH, Kim JI. 2000. Alpha-glucosidase inhibitory activities of some wild vegetable extracts. J Food Sci Nutr 5: 174-176
  39. Ratner RE. 2001. Controlling postprandial hyperglycemia. Am J Cardiol 88: 26H-31H
  40. Lebovitz HE. 1998. Postprandial hyperglycemic state: importance and consequences. Diabetes Res Clin Pract 40: S27-S28
  41. Baron AD. 1998. Postprandial hyperglycemia and $\alpha$-glucosidase inhibitors. Diabetes Res Clin Pract 40: S51-S55
  42. Inoue I, Takahashi K, Noji S, Awata T, Negishi K, Katayama S. 1997. Acarbose controls postprandial hyperproinsulinemia in non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 36: 143-151
  43. Soonthompun S, Rattarasarn C, Leelawattana R, Setasuban W. 1999. Postprandial plasma glucose: a good index of glycemic control in type 2 diabetic patients having nearnormal fasting glucose levels. Diabetes Res Clin Pract 46: 23-27
  44. Campbell RK, White JR, Nomura D. 2001. The clinical importance of postprandial hyperglycemia. Diabetes Educ 27: 624-637
  45. Bastyr EJ, Stuart CA, Brodows RG, Schwartz S, Graf CJ, Zagar A, Robertson KE (IOEZ Study Group). 2000. Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c. Diabetes Care 23: 1236-1241

Cited by

  1. Food protein-derived bioactive peptides in management of type 2 diabetes vol.54, pp.6, 2015,